Skip to main content
SpringerLink
Log in
Book cover

Current Review of Asthma pp 135–150Cite as

Inhaled Corticosteroids and Their Use in Asthma

  • Chapter

  • 182 Accesses

Abstract

Inhaled corticosteroids (ICSs) have revolutionized the treatment of asthma. They are the most potent and effective therapy for persistent asthma and are efficacious in most patients, regardless of age or asthma severity [l• •]. ICS use diminishes airway inflammation and hyperresponsiveness, improves lung function, and controls symptoms in asthmatic patients. Clinically, ICS use has been shown to reduce the number of emergency room visits, hospitalizations [2], and deaths [3• •]. Histologic studies have found that ICS use may even positively affect the natural course of asthma. However, dose-related adverse effects such as growth suppression and decreased bone mineral density (BMD) may limit ICS use for some patients.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. National Asthma Education and Prevention Program: Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health, Pub. No. 97–4051; 1997. This is a wonderful set of guidelines to help approach the treatment of patients with asthma.

    Google Scholar 

  2. Adams RJ, Fuhlbrigge A, Finkelstein JA, et al.: Impact of inhaled antiinflammatory therapy on hospitalization and emergency department visits for children with asthma. Pediatrics 2001, 107:706–711.

    Article  PubMed  CAS  Google Scholar 

  3. Suissa S, Ernst P, Benayoun S, et al.: Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000, 343:332–336. This landmark paper justifies the use of ICS in asthma.

    Article  PubMed  CAS  Google Scholar 

  4. Miesfeld RL, Bloom JW: Glucocorticoid receptor structure and function. In Inhaled Glucocorticoids in Asthma: Mechanisms and Clinical Actions. Edited by Schleimer RP, Busse WW, O’Byne PM. New York: Marcel Dekker; 1997:3–28.

    Google Scholar 

  5. Barnes PJ: Inhaled glucocorticoids for asthma. N Engl J Med 1995, 332:868–875.

    Article  PubMed  CAS  Google Scholar 

  6. Barnes PJ: Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol 1998, 102:531–538.

    Article  PubMed  CAS  Google Scholar 

  7. Barnes PJ: Effect of corticosteroid on airways hyperresponsiveness. Am J Respir Crit Care Med 1990, 141 (suppl):70–76.

    Google Scholar 

  8. Olivieri D, Chetta A, Del Donno M, et al.: Effect of short-term treatment of low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am J Respir Crit Care Med 1997, 155:1864–1871.

    Article  PubMed  CAS  Google Scholar 

  9. Haahtela T, Jarvinen M, Tuomo K, et al.: Comparison of a beta agonist terbutaline with an inhaled steroid, budesonide, in newly detected asthma. N Engl J Med 1991, 325:388–392.

    Article  PubMed  CAS  Google Scholar 

  10. Eisner MD, Lieu TA, Capra AM, et al.: Beta agonist, inhaled corticosteroids and the risk of intensive care unit admission for asthma. Eur Respir J 2001, 17:233–240. This is another great paper that provides a basis for continued ICS use in persistent asthma of varying severity.

    Article  PubMed  CAS  Google Scholar 

  11. Haahtela T, Jarvinen M, Kava T, et al.: Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994, 331:700–705.

    Article  PubMed  CAS  Google Scholar 

  12. Selroos O, Pretnalcho A, Lofroos AB, et al.: Effects of early and late interventions with inhaled corticosteroids in asthma. Chest 1995, 108:1228–1234.

    Article  PubMed  CAS  Google Scholar 

  13. Wenzel SE, Morgan K, Griffin R et al.: Improvement in health care utilization and pulmonary function with fluticasone propionate in patients with steroid-dependent asthma at a national asthma referral center. J Asthma 2001, 38:405–412.

    Article  PubMed  CAS  Google Scholar 

  14. Childhood Asthma Management Program Research Group: Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000, 343:1054–1063. This article sheds light on the treatment of asthma in children.

    Article  Google Scholar 

  15. Price JF, Weller PH: Comparison of fluticasone propionate and sodium cromoglycate for treatment of childhood asthma. Respir Med 1995, 89:363–368.

    Article  PubMed  CAS  Google Scholar 

  16. Galant SP, Lawrence M, Meltzer EO, et al.: Fluticasone propionate compared with theophylline for mild to moderate asthma. Ann Allergy Asthma Immunol 1996, 77:112–118.

    Article  PubMed  CAS  Google Scholar 

  17. Reed CE, Offord KP, Nelson HS, et al.: Aerosol beclomethasone dipropionate spray compared with theophylline as primary treatment for chronic mild to moderate asthma: the American Academy of Allergy, Asthma and Immunology Beclomethasone ipropionate Study Group. J Allergy Clin Immunol 1998, 101:14–23.

    Article  PubMed  CAS  Google Scholar 

  18. Lazarus SC, Boushey HA, Fahy JV, et al.: Long acting beta2-agonist monotherapy versus continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001, 285:2583–2593.

    Article  PubMed  CAS  Google Scholar 

  19. Malmstrom K, Rodriguez-Gomez, G, Guerra J, et al.: Oral montelukast, inhaled beclomethasone and placebo for chronic asthma: a randomized, controlled trial: Montelukast/Beclomethasone Study Group. Ann Intern Med 1999, 130:487–495.

    Article  PubMed  CAS  Google Scholar 

  20. Bleecker E, Welch MJ, Weinstein SF, et al.: Low-dose fluticasone propionate versus zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol 2000, 105:1123–1129.

    Article  PubMed  CAS  Google Scholar 

  21. Busse W, Raphael GD, Galant S, et al.: Low-dose fluticasone propionate compared with montelukast for first line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol 2001, 107:461–468.

    Article  PubMed  CAS  Google Scholar 

  22. Kim KT, Ginchansky EJ, Friedman BF, et al.: Fluticasone propionate versus zafirlukast: effect in patients previously receiving inhaled corticosteroid therapy. Ann Allergy Asthma Immunol 2000, 85:398–406.

    Article  PubMed  CAS  Google Scholar 

  23. Shrewbury S, Pyke S, Britton M: Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). Br Med J 2000, 320:1368–1373. This is a wonderful meta-analysis of the additive therapy, salmeterol.

    Article  Google Scholar 

  24. Baba K, Sakakibara A, Yagi T, et al.: Effects of theophylline withdrawal in well-controlled asthmatics treated with inhaled corticosteroid. J Asthma 2001, 38:615–624.

    Article  PubMed  CAS  Google Scholar 

  25. Li J, Mo H, Huang H: Effect of low dose inhaled corticosteroid combined with small dose of oral theophylline on treatment of bronchial asthma. Chin J Tuberculosis Respir Dis 2000, 23:336–339.

    CAS  Google Scholar 

  26. Laviolette M, Malmstrom K, Lu S, et al.: Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med 1999, 160:1862–1868.

    Article  PubMed  CAS  Google Scholar 

  27. Johnson M: Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol 1998, 101(suppl):434–439.

    Article  Google Scholar 

  28. Holt S, Suder A, Weatherall M, et al.: Dose response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. Br Med J 2001, 323:253–256.

    Article  CAS  Google Scholar 

  29. Kelly HW: Establishing a therapeutic index for the inhaled corticosteroids: part 1, pharmacokinetics/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol 1998, 102(suppl):36–51.

    Article  Google Scholar 

  30. Dempsey OJ, Wilson AM, Coutie WJ, et al.: Evaluation of the effect of a large volume spacer on the systemic bioactivity of fluticasone propionate metered dose inhaler. Chest 1999, 116:935–940.

    Article  PubMed  CAS  Google Scholar 

  31. Rubin BK, Kelly HW: The impact of drug delivery devices in asthma management. J Respir Dis 2002, 23(suppl A):36–43. An excellent review of devices for asthma medication and their efficacy.

    Google Scholar 

  32. Barnes PJ, Pedersen S, Busse WW: Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998, 157(suppl):l–53.

    Google Scholar 

  33. Schuh S, Johnson DW, Stephens D, et al.: Comparison of albuterol delivered by a metered dose inhaler with spacer versus nebulizer in children with mild acute asthma. J Pediatrics 1999, 135:22–27.

    Article  CAS  Google Scholar 

  34. Montreal Protocol: The Montreal Protocol on substances that deplete the ozone layer. Final Act (Nairobi: UNEP, 1987). Federal Register 1994, 59:56276–56298.

    Google Scholar 

  35. Vanden Burgt JA, Busse WW, Martin RJ, et al.: Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethsaone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol 2000, 106:1209–1226.

    Article  Google Scholar 

  36. Meakin BJ, Ganderton D, Panza I, et al.: The effect of flow rate on drug delivery from the Pulvinal, a high-resistance dry powder inhaler. J Aerosol Med 1998, 11:143–152.

    Article  PubMed  CAS  Google Scholar 

  37. Prime D, Parkes PA, Petchy L, et al.: Evaluation of the pharmaceutical performance of two dry powder inhalers: comparison of Diskus and Turbuhaler inhalers. Am J Respir Crit Care Med 1996, 153(suppl A):62.

    Google Scholar 

  38. Szefler SJ: A review of budesonide inhalation suspension in the treatment of pediatric asthma. Pharmacotherapy 2001, 21:195–206.

    Article  PubMed  CAS  Google Scholar 

  39. Allen DB. The safety of inhaled corticosteroids in the treatment of asthma. J Respir Dis 2002, 23(suppl A):16–26. This is an excellent review of the literature surrounding the side effects of ICS use.

    Google Scholar 

  40. Doull IJ, Freezer NJ, Holgate ST: Growth of prepubertal children with mild asthma treated with beclomethasone dipropionate. Am J Respir Crit Care Med 1995, 151:1715–1719.

    Article  PubMed  CAS  Google Scholar 

  41. Affrime MB, Kosoglou T, Thonoor CM, et al.: Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest 2000, 118:1538–1546.

    Article  PubMed  CAS  Google Scholar 

  42. Ayers JG, Bateman ED, Lundback B, et al.: High dose fluticasone propionate, 1 mg daily versus fluticasone 2 mg daily or budesonide 1.6 mg daily in patients with chronic severe asthma. International Study Group. Eur Respir J 1995, 8:579–586.

    Google Scholar 

  43. Li JT, Goldstein MF, Gross GN, et al.: Effects of fluticasone propionate, triamcinolone acetonide, prednisone and placebo on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol 1999, 103:622–629.

    Article  PubMed  CAS  Google Scholar 

  44. Li JT, Ford LB, Chervinsky P, et al.: Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma. J Allergy Clin Immunol 1999, 103:1062–1068.

    Article  PubMed  CAS  Google Scholar 

  45. Hodsman AB, Toogood JH, Jennings B, et al.: Differential effects of inhaled budesonide and oral prednisone on serum osteocalcin. J Clin Endocrinol Metab 1991, 72:530–540.

    Article  PubMed  CAS  Google Scholar 

  46. Villareal Ms, Klaustermeyer WB, Hahn TJ, et al.: Osteoporosis in steroid-dependent asthma. Ann Allergy Asthma Immunol 1996, 76:369–372.

    Article  PubMed  CAS  Google Scholar 

  47. Wong CA, Walsh LJ, Smith CJ, et al.: Inhaled corticosteroid use and bone mineral density on patients with asthma. Lancet 2000, 355:1399–1403.

    Article  PubMed  CAS  Google Scholar 

  48. Meeran K, Hattersley A, Burrin J, et al.: Oral and inhaled corticosteroids reduce bone formation as shown by plasma osteocalcin levels. Am J Respir Crit Care Med 1995, 151:333–336.

    Article  PubMed  CAS  Google Scholar 

  49. Tinkelman DG, Reed CE, Nelson HS, Offord KP: Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children [see comments]. Pediatrics 1993, 92:144–146.

    Google Scholar 

  50. Allen DB, Bronsky EA, LaForce CF, et al.: Growth in asthmatic children treated with fluticasone propionate: Fluticasone Propionate Asthma Study Group. J Pediatrics 1998, 132:472–477.

    Article  CAS  Google Scholar 

  51. Price JF, Russell G, Hindmarsh PD, et al.: Growth during one year of treatment with fluticasone propionate or sodium cromoglycate in children with asthma. Pediatr Pulmonol 1997,24:178–186. This is a reassuring study of growth in ICS-treated children that is of long duration and is nicely controlled.

    Article  PubMed  CAS  Google Scholar 

  52. Agertoft L, Pedersen S: Effect of long term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000, 343:1064–1069.

    Article  PubMed  CAS  Google Scholar 

  53. Toogood JH, Markov AE, Baskerville J, et al.: Association of ocular cataracts with inhaled and oral steroid therapy during long term treatment of asthma. J Allergy Clin Immunol 1993, 91:571–579.

    Article  PubMed  CAS  Google Scholar 

  54. Simons FE, Persaud MP, Gillespie CA, et al.: Absence of posterior subcapsular cataracts in patients treated with inhaled glucocorticoids. Lancet 1993, 342:776–778.

    Article  PubMed  CAS  Google Scholar 

  55. Dubus JC, Marguet C, Deschildre A, et al.: Local side effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age and device. Allergy 2001, 56:944–948.

    Article  PubMed  CAS  Google Scholar 

  56. Toogood JH, White FA, Baskerville JC, et al.: Comparison of the antiasthmatic, oropharyngeal and systemic glucocorticoid effects of budesonide administered through a pressurized aerosol plus spacer or the Turbuhaler dry powder inhaler. J Allergy Clin Immunol 1997, 99:186–193.

    Article  PubMed  CAS  Google Scholar 

  57. Toogood JH, Jennings B, Greenway RW, et al.: Candidiasis and dysphonia complicating beclomethasone treatment of asthma. J Allergy Clin Immunol 1980, 65:145–153.

    Article  PubMed  CAS  Google Scholar 

  58. Jenkins C, Woolcock AJ, Saarelainen P, et al.: Salmeterol/fluticasone propionate combination therapy 50/250 twice daily is more effective than budesonide 800 meg twice daily in treating moderate to severe asthma. Respir Med 2000, 94:715–723.

    Article  PubMed  CAS  Google Scholar 

  59. Nelson HS: Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma. J Allergy Clin Immunol 2001, 107:397–416.

    Article  Google Scholar 

Download references

Authors
  1. Kerry L. Drain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James T. C. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine, George Washington University School of Medicine, Washington, DC, USA

    Michael A. Kaliner MD (Professor, Medical Director) (Professor, Medical Director)

  2. Institute for Asthma and Allergy, Wheaton, Maryland, USA

    Michael A. Kaliner MD (Professor, Medical Director) (Professor, Medical Director)

  3. Institute for Asthma and Allergy, Chevy Chase, Maryland, USA

    Michael A. Kaliner MD (Professor, Medical Director) (Professor, Medical Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Drain, K.L., Li, J.T.C. (2003). Inhaled Corticosteroids and Their Use in Asthma. In: Kaliner, M.A. (eds) Current Review of Asthma. Current Medicine Group, London. https://doi.org/10.1007/978-1-4613-1095-2_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1095-2_15

  • Publisher Name: Current Medicine Group, London

  • Print ISBN: 978-1-4757-0810-3

  • Online ISBN: 978-1-4613-1095-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation